It is estimated that 1.2 million infants die annually from birth asphyxia and its complication, hypoxic- ischemic (HI) brain injury. In U.S. neonatal HI-brain injury remains one of the major causes for a life-long neurological disability in children. This indicates an urgent need to develop therapeutic strategies based on a better understanding the mechanisms of HI injury in the developing brain. Mitochondrial dysfunction is the most fundamental biological event leading to neuronal injury in this disease. Although, mitochondrial complex-I (C-I) is severely inhibited by a HI insult, upon re-oxygenation/reperfusion the energy-generating function of C-I rapidly recovers. This reperfusion-driven re-activation of C-I is tightly linked to the generation of reactive oxygen species (ROS). We hypothesize that the inhibition of mitochondrial C-I recovery upon reperfusion represents a therapeutic strategy against an oxidative burst during early reperfusion. We show that compared to controls, mice exposed to C-I inhibitor, pyridaben exhibited significant attenuation of cerebral injury, despite a sluggish recovery of the C-I linked mitochondrial respiration. Mitochondria isolated from these pyridaben-exposed HI-mice demonstrated a limited acceleration in ROS production during reperfusion. This suggests that during reperfusion post-HI restoration of electron transport flow in the C-I contributes not only to cellular recovery, but also to cellular injury.
Specific aims are designed to determine;
Aim 1, whether an inhibition of the C-I recovery during reperfusion attenuates oxidative damage to mitochondrial matrix and as a result, increases mitochondrial tolerance to Ca++ induced opening of permeability transition pore (PTP).
and Aim 2, whether hypoxemia during reperfusion slow down reactivation of mitochondrial C-I and whether this protects brain against reperfusion-driven oxidative stress Thus, the project is designed to establish both, mechanistic rationale and a clinical translation for an innovative therapeutic concept of a gradual metabolic recovery of the C-I directed against reperfusion-driven oxidative stress.

Public Health Relevance

This proposal is focused to develop a novel therapeutic concept for protection of the ischemic brain against reperfusion-driven oxidative stress. Potential implication of this research is very broad, because an ischemic brain injury (stroke, hypoxic-ischemic encephalopathy) is a leading cause for neurological handicap in adults and children.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Developmental Brain Disorders Study Section (DBD)
Program Officer
Bosetti, Francesca
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Sosunov, Sergey A; Ameer, Xavier; Niatsetskaya, Zoya V et al. (2015) Isoflurane anesthesia initiated at the onset of reperfusion attenuates oxidative and hypoxic-ischemic brain injury. PLoS One 10:e0120456
Utkina-Sosunova, Irina V; Niatsetskaya, Zoya V; Sosunov, Sergey A et al. (2013) Nelfinavir inhibits intra-mitochondrial calcium influx and protects brain against hypoxic-ischemic injury in neonatal mice. PLoS One 8:e62448
Niatsetskaya, Zoya V; Sosunov, Sergei A; Matsiukevich, Dzmitry et al. (2012) The oxygen free radicals originating from mitochondrial complex I contribute to oxidative brain injury following hypoxia-ischemia in neonatal mice. J Neurosci 32:3235-44
Niatsetskaya, Zoya V; Charlagorla, Pradeep; Matsukevich, Dzmitry A et al. (2012) Mild hypoxemia during initial reperfusion alleviates the severity of secondary energy failure and protects brain in neonatal mice with hypoxic-ischemic injury. J Cereb Blood Flow Metab 32:232-41
Wang, Xiaoyang; Leverin, Anna-Lena; Han, Wei et al. (2011) Isolation of brain mitochondria from neonatal mice. J Neurochem 119:1253-61